We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Take SEM Off the Menu? Executive Chairman Gives Premium Offer
Read MoreHide Full Article
Key Takeaways
SEM received a non-binding take-private proposal offering $16 to $16.20 per share.
The bid comes from Executive Chairman Robert A. Ortenzio, signaling interest in private control.
The move follows a 63.8% stock drop and a valuation below SEM's five-year median and industry average.
Select Medical Holdings Corporation (SEM - Free Report) announced that its executive chairman has submitted a take-private proposal to the board. The company acknowledged the proposal publicly, indicating the board is reviewing it. The non-binding indication of interest signals a payment of $16 to $16.20 per share for the outstanding stocks. It indicates a premium of up to 15.6% from Monday’s closing price of $14.01.
The proposal comes from Robert A. Ortenzio, executive chairman, co-founder and director, meaning someone already holding a leadership stake is offering to buy out the public shares and convert the company to private ownership. While this is not yet a definitive agreement, but it opens the door to negotiations. The move suggests the executive believes there is value in the business that may be unlocked off-market.
Take-private deals change the whole dynamic of a company. For shareholders, it means the public market liquidity disappears and the risk/return profile shifts. For SEM, a take-private means the company may be able to act with more strategic flexibility and possibly execute longer-term plans. It also signals confidence from the insider leadership that the company is undervalued or has significant upside.
Over the past year, SEM plunged 63.8%, underperforming the industry’s 42.3% decline, due to worries about sustainability, rising costs, uncertainty around government funding and other sector-wide challenges.
Image Source: Zacks Investment Research
This has led to a valuation of 10.43X forward earnings, lower than its five-year median of 12.32X and the industry average of 15X. Its rehabilitation hospital segment witnesses rising occupancy, admissions and patient days.
The Zacks Consensus Estimate for Aveanna’s current-year earnings indicates an 800% year-over-year improvement. The consensus mark for Aveanna’s revenues of $2.4 billion implies 18% growth from the year-ago period.
The Zacks Consensus Estimate for The Pennant Group’s 2025 earnings implies a 22.3% increase from the year-ago reported figure. PNTG beat earnings estimates in three of the trailing four quarters and missed once, with an average surprise of 6.5%. The consensus mark for The Pennant Group’s current-year revenues is pegged at $932.7 million, which indicates a 34.2% year-over-year increase.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
Take SEM Off the Menu? Executive Chairman Gives Premium Offer
Key Takeaways
Select Medical Holdings Corporation (SEM - Free Report) announced that its executive chairman has submitted a take-private proposal to the board. The company acknowledged the proposal publicly, indicating the board is reviewing it. The non-binding indication of interest signals a payment of $16 to $16.20 per share for the outstanding stocks. It indicates a premium of up to 15.6% from Monday’s closing price of $14.01.
The proposal comes from Robert A. Ortenzio, executive chairman, co-founder and director, meaning someone already holding a leadership stake is offering to buy out the public shares and convert the company to private ownership. While this is not yet a definitive agreement, but it opens the door to negotiations. The move suggests the executive believes there is value in the business that may be unlocked off-market.
Take-private deals change the whole dynamic of a company. For shareholders, it means the public market liquidity disappears and the risk/return profile shifts. For SEM, a take-private means the company may be able to act with more strategic flexibility and possibly execute longer-term plans. It also signals confidence from the insider leadership that the company is undervalued or has significant upside.
Over the past year, SEM plunged 63.8%, underperforming the industry’s 42.3% decline, due to worries about sustainability, rising costs, uncertainty around government funding and other sector-wide challenges.
This has led to a valuation of 10.43X forward earnings, lower than its five-year median of 12.32X and the industry average of 15X. Its rehabilitation hospital segment witnesses rising occupancy, admissions and patient days.
SEM’s Zacks Rank & Other Key Picks
Select Medical currently has a Zacks Rank #2 (Buy). Some other top-ranked and promising stocks in the broader Medicalsector are Aveanna Healthcare (AVAH - Free Report) and The Pennant Group (PNTG - Free Report) , each carrying a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Zacks Consensus Estimate for Aveanna’s current-year earnings indicates an 800% year-over-year improvement. The consensus mark for Aveanna’s revenues of $2.4 billion implies 18% growth from the year-ago period.
The Zacks Consensus Estimate for The Pennant Group’s 2025 earnings implies a 22.3% increase from the year-ago reported figure. PNTG beat earnings estimates in three of the trailing four quarters and missed once, with an average surprise of 6.5%. The consensus mark for The Pennant Group’s current-year revenues is pegged at $932.7 million, which indicates a 34.2% year-over-year increase.